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GENERAL INTRODUCTION 
The folate metabolism antagonist, methotrexate (MTX), a structural analog of 
folic acids, inhibits dihydrofolate reductase that reduces dihydrofolate to 
tetrahydrofolate. MTX therefore limits the availability of one-carbon fragments 
necessary for the synthesis of purines, and interferes with the conversion of 
deoxyuridylate to thymidylate in the synthesis of DNA (Lloyd et al., 1999; Genestier 
et al., 2000; Hyoun et al., 2012). This results in MTX-mediated inhibition of cell 
proliferation, disruption of cell cycle and induction of apoptosis in susceptible cells 
(Genestier et al., 2000). MTX has historically been used as an antineoplastic agent 
(Wright et al., 1951) but has had a broader role in several areas of medicine in the past 
2 decades (Kremer and Phelps, 1992; Kumar et al., 1994). More recently, it has been 
used in the treatment of gestational trophoblast disease, and autoimmune diseases 
such as rheumatoid arthritis, systemic lup
and psoriatic arthritis (Cuellar and Espinoza, 1997; DeLoia et al., 1998; Genestier et 
al., 2000; Cronstein, 2005). MTX is also used as an abortifacient, both for the 
voluntary termination of pregnancy and for the medical management of ectopic 
pregnancy (Kozma and Ramasethu, 2011). 
In humans, maternal exposure to MTX during critical periods of 
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embryogenesis induces miscarriages and embryopathy (Del Campo et al., 1999; 
Martinez et al., 2009). The previous case reports in human showed that embryopathy 
such as nervous system anomalies, growth retardation, craniofacial deformities and 
skeletal defects, resulted from failed attempts at termination of pregnancy with MTX 
or when mothers who are taking MTX for medical reasons become pregnant 
inadvertently (Bawle et al., 1998; Lloyd et al., 1999; Seidahmed et al., 2006; 
Corona-Rivera et al., 2010; Hyoun et al., 2012). In experimental animals, prenatal 
MTX exposure reportedly induced resorption, intrauterine death, hypotrophy or 
congenital malformations in rats, mice and rabbits (Skalko and Gold, 1974; Tsibangu 
et al., 1975; Jordan et al., 1977), and slight embryolethality in rhesus monkeys 
(Wilson et al., 1979). However, despite the fact that the placenta is one of the 
important organs for evaluation of risks for the dam and embryo, few researchers have 
sufficiently focused on the detailed histopathological findings of the placenta exposed 
to MTX to date. 
As for the brain anomalies in MTX-induced embryopathy in humans, clinical 
findings of alobar/semilobar holoprosencephaly (Seidahmed et al., 2006; 
Corona-Rivera et al., 2010), cerebellar hypoplasia (Seidahmed et al., 2006), agenesis 
of the corpus callosum (Seidahmed et al., 2006) and microcephaly (Bawle et al., 1998; 
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Garcia-Minaur and Botella, 2000) have been reported. Moreover, prenatal MTX 
exposure reportedly induced a decrease in net weights of the brain in chicken, and 
hydrocephalus in rabbits. Nevertheless, detailed histopathological findings and 
pathogenesis of MTX-induced brain anomalies in fetus of human and experimental 
animals remain unclear. 
The present studies were carried out to clarify the toxic effects of prenatal 
MTX administration on the placenta and fetal brain. In chapter 1, we performed the 
sequential histopathological examinations in the placenta after exposure to MTX in 
pregnant rats. In chapter 2, we examined histopathologically the time-dependent 
changes of fetal brain following MTX administration to their dams. The purpose of 
the present study is to elucidate the pathogenesis of the damage of placenta and fetal 
brain induced by MTX. 
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CHAPTER 1  
Effect of Methotrexate on Rat Placenta Development 
5 
1.1 Introduction 
The placenta is an interface between the dams and the embryos/fetuses, and is 
a multifaceted organ that performs a number of essential and significant functions that 
are modified during gestation. These include anchoring the developing fetus to the 
uterine wall, mediating maternal immune tolerance, and maintaining O2/CO2
exchange and nutrient/metabolite requirements during embryonic development (Bauer 
et al., 1998; Furukawa et al., 2011). It also functions as a barrier protecting 
embryos/fetuses from xenobiotics, and releases a variety of steroids, hormones and 
cytokines (Furukawa et al., 2011). Thus, the growth and function of the placenta play 
important roles in the maintenance of pregnancy, and influences fetal development. 
The placenta is a target organ highly susceptible to drug- or chemical 
material-induced adverse effects (Furukawa et al., 2011). Drug- or chemical 
material-induced placental functional disorders result in developmental abnormality 
of the fetus (Furukawa et al., 2011). Thus, the placenta is an important organ for 
evaluating embryonic developmental toxicity and understanding its mechanism. 
Folates function in various one-carbon transfer reactions, including purine and 
thymidylate biosynthesis, amino acid metabolism, and formate oxidation (Wagner, 
1995). Purine and thymidylate biosynthesis is a fundamental requisite event 
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underlying DNA and RNA synthesis (Tamura and Picciano, 2006). These 
folate-dependent reactions are essential for fetal development and maternal well-being 
(Tamura and Picciano, 2006). Folic acid may also have important roles in other 
physiological pathways needed for successful pregnancy, including angiogenesis 
(Sasaki et al., 2003; Williams et al., 2011), methylation of the homocysteine (Ciaccio 
et al., 2008), antioxidant effect (Joshi et al., 2001), and endothelial-dependent vascular 
relaxation (Griffith et al., 2005). These processes are essential for the establishment of 
fetoplacental circulation. However, little is known about histopathological changes in 
placentas induced by folate metabolism impairment or folate deficiency.  
Folate metabolism antagonist, methotrexate (MTX), a structural analog of 
folic acids, inhibits the reduction of dihydrofolate to tetrahydrofolate, resulting in the 
inhibition of DNA and RNA synthesis (Margolis et al., 1971; Jolivet et al., 1983). This 
results in MTX-mediated inhibition of cell proliferation, disruption of cell cycle and 
induction of apoptosis in susceptible cells (Genestier et al., 2000). MTX has been 
used in the treatment of neoplastic diseases, gestational trophoblast disease, and 
autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, 
et al., 1998; Genestier et al., 2000). MTX is also used in the medical management of 
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ectopic pregnancy and for medical termination of pregnancy (Creinin and Krohn, 
1997; Lipscomb, 2007). In humans, maternal exposure to MTX during pregnancy 
induces miscarriages, neonatal malformations and developmental delays (Del Campo 
et al., 1999; Martinez Lopez et al., 2009). MTX is embryotoxic and teratogenic in rats, 
mice and rabbits (Skalko and Gold, 1974; Tsibangu et al., 1975; Jordan et al., 1977), 
and is abortifacient in rhesus monkeys (Wilson et al., 1979). However, there have 
been few reports on the detailed histopathological findings of the placenta exposed to 
MTX, and it remains unclear how placental pathology might affect fetal growth. In 
the present study, we investigated the sequential histopathological changes in the 
placenta after exposure to MTX in pregnant rats to clarify the role of the placenta in 
the induction of fetal developmental disability induced by folate metabolism 
antagonist, MTX. 
1.2 Materials and methods  
1.2.1 Animals  
All experiments were performed using female Wistar Imamichi rats, 9 weeks 
of age, 223.66 ± 1.69 g (mean ± SE) in weight and obtained from the Institute of 
Animal Reproduction (Ibaraki, Japan). The animals were reared in a room with the 
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temperature controlled at 22 ± 2 C, humidity at 50 ± 5%, with ventilation 11 times 
per hour and lighting set at 12:12-h light/dark cycle (light cycle, 7:00-19:00), and they 
were given standard chow (CE-2; Nihon Clea, Tokyo, Japan). The present 
experiments were performed following the provisions approved by the Animal 
Research Committee of Tottori University.  
1.2.2 Experimental design  
Day 0 of gestation (GD 0) was designated as the day when the presence of a 
vaginal plug was identified. A total of 44 animals were divided into three different 
groups as follows: (1) saline-treated control rats (n = 16), (2) MTX-GDs 11 and 
12-treated rats (n = 16), (3) MTX-GDs 13 and 14-treated rats (n = 12). MTX (Pfizer 
Japan Inc., Tokyo, Japan) was dissolved in saline and administered intraperitoneally. 
The rats received intraperitoneal injections (i.p.) with MTX (0.2 mg/kg body weight) 
or saline (the control) during GDs 11-12 or GDs 13-14. The dose level in the present 
study was previously reported to induce an impairment of the fetus in rats (Jordan et 
al., 1977; Wilson et al., 1979). The specific timing of MTX administration was 
selected because the glycogen cells, which constitute one of the important elements in 
the basal zone, are detected from GD 11 (Peel and Bulmer, 1977). Maternal body 
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weight was recorded on GDs 0-21. Placenta and fetus samples were collected under 
pentobarbital anesthesia (100 mg/kg, i.p.) on GDs 13 (except for the GD13,14-treated 
group), 15, 17 and 21. All embryos/fetuses were removed from the placentas. Half of 
the placentas were separated between the basal zone and decidua basalis, removed 
from the uterine wall, and weighed. The embryos/fetuses and removed placentas were 
weighed. The fetuses on GD21 were macroscopically examined for external 
malformations. All procedures were conducted between 9 and 11 a.m.  
1.2.3 Histopathological examination of rat placentas  
All placentas were fixed in 10% neutral buffered formalin. These tissues were 
embedded in paraffin, sectioned 4 µm in thickness, and stained with hematoxylin and 
eosin (HE). The thickness of the labyrinth zone, basal zone, decidua basalis and 
metrial gland close to the central portion were measured in placentas from each dam 
with histomorphometric analysis software (Olympus Corporation, Tokyo, Japan).  
1.2.4 Immunohistochemical examinations of rat placentas  
For immunohistochemistry, mouse monoclonal antibodies for 
Phospho-Histone H3 (Epitomics, Inc., CA, USA) were used as the primary antibodies. 
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All sections were dewaxed, rehydrated, rinsed with 0.05 M Tris-buffered saline (TBS; 
pH 7.6), treated with 3% hydrogen peroxide, and then rinsed again with TBS. Tissue 
sections for detection of both antigens were immersed in 0.01 M citrate buffer (pH 
6.0/Dako, Glostrup, Denmark) and autoclaved for 15 min at 121 C to retrieve the 
antigens. Slides were incubated with the primary antibody (1:300 dilution) for 30 min 
at room temperature, rinsed with TBS, and treated with Simple Stain MAX-PO 
(Nichirei, Tokyo, Japan) for 30 min at room temperature. They were then rinsed with 
TBS before being treated with a 3,3 -diaminobenzidine solution containing 0.01% 
hydrogen peroxide to facilitate a peroxidase color reaction. After a further wash with 
Apoptotic bodies in the placenta were detected by terminal 
deoxynucleotidyl-transferase (TdT)-mediated deoxyuridine triphosphate-digoxigenin 
(dUTP) nick-end labeling (TUNEL), which was performed using an in situ apoptosis 
detection kit (Trevigen, Inc., Gaithersburg, MD, USA). The criteria of apoptosis 
included TUNEL staining and the presence of pyknotic nuclei. The number of 
TUNEL or Phospho-Histone H3-positive cells was counted in ten different fields in 
the labyrinth and the basal zones by light microscopy with a 20× objective lens, and 
with above-mentioned histomorphometric analysis software.  
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1.2.5 Statistical analysis  
All data were expressed as means ± standard error (SE) in each group. The 
t-
comparison test with statistical software (SSRI Co., Ltd., Tokyo, Japan). P < 0.05 or P
< 0.01 was considered to be statistically significant.  
1.3 Results  
1.3.1 Effects on dams  
Body weight gains of dams decreased significantly during GDs 13-21 in the 
GD11,12-treated group compared with the control group, whereas in the 
GD13,14-treated group, significant declining body weight gains of dams were not 
observed throughout the experimental period compared with the control group (Fig. 1). 
However, dams neither in the control nor the two MTX-treated groups showed any 
other clinical signs during the experimental period. 
1.3.2 Effects on embryos/fetuses and placentas  
In the GD11,12-treated group, the number of living fetuses per litter tended to 
decrease and the fetal mortality rates tended to increase throughout the experimental 
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period (Table 1). The fetal weights were significantly reduced on GD 13 and the 
placen-tal weights were significantly reduced on GDs 13 and 15 in the 
GD11,12-treated group (Table 1). The placentas on GD 17 were macroscopically 
small (Fig. 2). In the GD11,12-treated group, no macroscopic fetal abnormalities were 
observed in the external examination on GD21. No significant macroscopical changes 
were detected in placentas and fetuses of the GD13,14-treated group.  
1.3.3 Histopathological findings of placentas  
In the GD11,12-treated group, a marked thinning of basal zone was detected 
on GD13 and this significant pathological change was continued throughout the 
experimental period, whereas the thickness of the labyrinth zone decreased 
significantly during GDs 13-17 (Figs. 3 and 4). The severity of thinning of the basal 
zone was higher than that of the labyrinth zone (Figs. 3 and 4). In the basal zone of 
the GD11,12-treated group, there were significant decreases in both 
spongiotrophoblasts and trophoblastic giant cells on GD13, compared with those of 
the control group (Fig. 4c and d). In addition, a significant decrease in mitotic cells 
and Phospho-Histone H3-positive cells was detected in basal zone of GD11,12-treated 
group on GD13, compared with the control group (Figs. 4, 6 and 7). Apoptotic cells, 
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which were characterized by pyknosis or karyorrhexis, phagocytosis and cell debris, 
and positively stained by the TUNEL method, increased significantly on GD 13 in the 
basal zone of the GD11,12-treated group (Figs. 4, 6 and 7). There were no significant 
differences in the number of Phospho-Histone H3-positive cells and TUNEL-positive 
cells in the labyrinth zone between the control group and the GD11,12-treated group 
throughout the experimental period (Fig. 7). A marked decrease in glycogen 
cell-islands in the basal zone was detected, and there was a reduction in the interstitial 
invasion of glycogen cell-like trophoblasts into the metrial gland on GD 15 in the 
GD11,12-treated group (Fig. 5). No significant histopathological changes in the 
decidua basalis and metrial gland were noted throughout the experimental period in 
the GD11,12-treated group. In the GD13,14-treated group, there were no other 
significant histopathological changes in the placentas than thinning of the labyrinth 
zone on GD 17.  
1.4 Discussion  
In the present study, the administration of MTX at 0.2 mg/kg/day during GDs 
11-12 induced a significant thinning of the basal zone during the experimental period, 
and the labyrinth zone only on GDs 13, 15 and 17. The severity of thinning of the 
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basal zone was higher than that of the labyrinth zone. In the GD11,12-treated group, a 
significant decrease of cell proliferation marker, Phospho-Histone H3-positive cells, 
and a major increase in apoptotic marker, TUNEL-positive cells, were detected on 
GD13 in the basal zone. By contrast, in the GD13,14-treated group, there were no 
other significant changes in placentas and fetuses throughout the experimental period 
than thinning of the labyrinth zone on GD 17. These results indicated that component 
cells in the basal and labyrinth zones on GDs 11-12 are more highly sensitive to MTX 
than those of GDs 13-14.  
In normal rat placentas of GDs 11-21, a cell proliferation marker, PCNA 
expression in trophoblasts, fetal vessel endothelial cells of the labyrinth zone, and 
spongiotrophoblasts of the basal zone were highest on GD 11 and 13, and decreased 
as pregnancy progressed (Acar et al., 2008). These results showed that trophoblasts 
and spongiotrophoblasts on GDs 11-12 have higher cell-proliferative activity than 
those of GDs 13-14. This is related to the higher sensitivity to MTX of their 
component cells in the basal and labyrinth zones of GDs 11-12 than those of GDs 
13-14. In normal human placentas, PCNA expression in cytotrophoblasts is highest in 
the very early term of pregnancy and significantly decreases with the advance of 
pregnancy (Ishihara et al., 2000). It is speculated that the toxic effects of MTX on 
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placental development are diminished with the advance of pregnancy after 
mid-gestation.  
In the present study, MTX exposure on GDs 11-12 induced not only labyrinth 
zone hypoplasia during GDs 13-17 but also severe hypoplasia of basal zone 
throughout the experimental period. The hypoplasia of the basal zone was more 
severe than that of the labyrinth zone. Although there were few reports describing 
detailed histopathological findings of placental lesions induced by anti-cancer drugs, 
the effects of cisplatin or 6-mercaptopurine on rat placental development have been 
previously studied (Furukawa et al., 2008, 2013). In the previous study, cisplatin 
exposure on GDs 11-12 induced severe hypoplasia in both the labyrinth basal zones 
(Furukawa et al., 2013) and 6-mercaptopurine exposure on GDs 11-12 induced more 
severe hypoplasia of the labyrinth zone than that of the basal zone (Furukawa et al., 
2008). These results may suggest that it is possible that MTX affects the component 
cells in the basal zone of GDs 11-12 more strongly than those in the labyrinth zone of 
GDs 11-12, compared with cisplatin or 6- mercaptopurine. Additionally, from a result 
of the present study, it is hypothesized that folate metabolism is carried out more 
actively in the basal zone of GDs 11-12 than labyrinth zone of GDs 11-12. Recent 
study demonstrated that folic acid has important roles in physiological pathways 
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needed for placental development including extravillous trophoblast invasion, 
angiogenesis, and secretion of MMPs (Williams et al., 2011). The risks of 
placenta-mediated adverse outcome such as preeclampsia and placental abruption 
were greater for women exposed to folic acid antagonists during pregnancy than 
women without such exposure (Wen et al., 2008). However, little attention has been 
given to the developmental stage and site of the placenta strongly affected by folate 
metabolism impairment or folate deficiency have been clarified. This is the first study 
demonstrating that the basal zone is strongly affected by folate metabolism antagonist. 
These results can be useful in order to prevent the occurrence of a placenta-mediated 
adverse outcome induced by folate metabolism impairment and folate deficiency.  
The basal zone is comprised of three differentiated cell types: (1) 
spongiotrophoblasts, (2) trophoblastic giant cells and (3) glycogen cells (Ain et al., 
2003). The trophoblastic giant cells are analogous to human extravillous 
cytotrophoblast cells and located at the maternal-placental interface (Soares et al., 
1996). These cells stop dividing and continue to replicate DNA (endoreduplication) to 
become polyploidy (Soares et al., 1996; Watson and Cross, 2005). The 
spongiotrophoblasts directly originate from the ectoplacental cone and are located 
immediately above the trophoblastic giant cell layer. Although spongiotrophoblasts 
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are morphologically distinct from trophoblast giant cells, both of them exhibit 
endocrine activities (Soares et al., 1996). Glycogen cells are characterized by a 
vacuolated glycogen-rich cytoplasm and appear as compact cell islets (Davies and 
Glasser, 1968; Bouillot et al., 2006). Glycogen cells are detected in the 
spongiotrophoblasts layer in mid-gestation, and disappear at the end of pregnancy 
(Davies and Glasser, 1968). The trophoblasts originated from the glycogen cells 
invade the decidua and metrial gland (Furukawa et al., 2011). The 
spongiotrophoblasts and trophoblastic giant cells in the basal zone produce a 
prolactin-like hormone with lactogens and cytokines during pregnancy to maintain 
progesterone secretion from the corpus luteum (Ain et al., 2003; Malassiné et al., 
2003; Soares, 2004). It has been suggested that another function of the basal zone is to 
limit the growth of maternal endothelium into the fetal placenta (Coan et al., 2006). 
Spongiotrophoblasts produce anti-angiogenic proteins such as Flt1 (an antagonist of 
VEGF) and Prp (an antagonist of Plf) (He et al., 1999). Although their initial 
appearance within the spongiotrophoblast layer and their expression of 
spongiotrophoblast-specific genes imply that glycogen cells are a specialized subtype 
of spongiotrophoblast cell (Adamson et al., 2002), the developmental origin of 
glycogen cells is not entirely clear. Although the functions of glycogen cells have 
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been unclear, it is speculated that they are related with glycogen metabolism because 
glucagons are detected in glycogen cells (Coan et al., 2006). It is possible that the 
decrease in the number of living fetuses per litter and the increase of fetal mortality in 
the present study are related to a decrease in spongiotrophoblasts and glycogen cells; 
namely, basal zone hypoplasia. After this study, it is expected that a clarification of the 
relation between basal zone hypoplasia and abnormal fetal development will take 
place.  
In conclusion, MTX administration at 0.2 mg/kg/day during GDs 11-12 
induced developmental retardation of the basal and labyrinth zones, leading to small 
placentas, though MTX treatment during GDs 13-14 induced few pathological 
changes in the placenta. The severity of developmental retardation of the basal zone 
induced by MTX exposure during GDs 11-12 was higher than that of the labyrinth 
zone. It is considered that the component cells of the basal and labyrinth zones on 
GDs 11-12 are more highly sensitive to MTX than those on GDs 13-14 and that the 
component cells of the basal zone are more sensitive to MTX than those of the 
labyrinth zone. To our knowledge, this is the first report demonstrating 
histopathological findings of placental developmental retardation induced by MTX. 
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Table 1. Effects of methotrexate on fetuses and placentas 
Values are expressed as means ± SE. 
*: P<0.05, compared with control (Student's t-test). 
. 
. 
Autopsy Treatment Day of treatment
No. of 
dams 










GD13 Control - 4 66 16.50 ± 1.04 4.53 ± 2.97 0.070 ± 0.004 0.096 ± 0.006
 MTX 11, 12 4 49 12.25 ± 1.89 25.48 ± 11.74 0.054 ± 0.003* 0.083 ± 0.013*
GD15 Control - 4 63 15.75 ± 0.48 0.00 ± 0.00 0.267 ± 0.008 0.215 ± 0.011
 MTX 11, 12 4 36 9.00 ± 2.04 30.28 ± 9.64 0.252 ± 0.010 0.163 ± 0.013
  13, 14 4 59 14.75 ± 0.63 2.94 ± 2.94 0.250 ± 0.010 0.220 ± 0.010
GD17 Control - 4 58 14.50 ± 1.56 2.08 ± 2.08 0.815 ± 0.009 0.319 ± 0.005
 MTX 11, 12 4 47 11.75 ± 2.17 22.38 ± 12.94 0.842 ± 0.015 0.259 ± 0.026
  13, 14 4 55 13.75 ± 1.03 5.42 ± 1.85 0.820 ± 0.013 0.284 ± 0.031
GD21 Control - 4 68 17.00 ± 0.71 1.39 ± 1.39 5.000 ± 0.050 0.447 ± 0.013
 MTX 11, 12 4 39 9.75 ± 2.21 11.39 ± 4.98 5.217 ± 0.074 0.472 ± 0.015
  13, 14 4 64 16.00 ± 0.91 0.00 ± 0.00 5.071 ± 0.140 0.432 ± 0.011
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Fig. 1 Body weight gains of dams decreased significantly during GDs 13-21 in the 
GD11,12-treated group compared with the control group (a), whereas in the 
GD13,14-treated group, significant declining body weight gains of dams were not 
observed throughout the experimental period compared with the control group (b). : 
Control. : GD11,12-treated group. : GD13,14-treated group. Values are 
expressed as means ± SE. *: P<0.05, compared with control (Student's t-
P<0.01, compared with control (Student's t-test). 
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Fig. 2. Gross appearance of placenta on GD17 of the control (left) and the 
GD11,12-treated group (right). The placenta in GD11,12-treated group was 
macroscopically smaller than that of control. The ruler in the figure is graduated in 
millimeters. 
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Fig. 3. Thickness of the labyrinth zone, basal zone, decidua basalis and metrial gland. 
: Control. : GD11,12-treated group. : GD13,14-treated group. Values are 
expressed as means ± SE. *: P<0.01, compared with control (Student's t-
compared with control (Dunnett's multiple comparison test).  
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Fig. 4. Histopathological findings of placentas on GD13 of control (a, c and e) and 
GD11,12-treated group (b, d and f). (L) Labyrinth zone, (BS) Basal zone 
spongiotrophoblast layer, (BT) Basal zone trophoblastic giant cell layer, (D) Decidua 
basalis. (a and b) Bar=200 m, (c and  and 
power field in control. (b) Low power field in GD11,12-treated group. Marked 
thinning of basal and labyrinth zones was observed. (c) Basal zone of the control, both 
spongiotrophoblasts and trophoblastic giant cells were observed. (d) In the basal zone 
of the GD11,12-treated group, both spongiotrophoblasts and trophoblastic giant cells 
were significantly diminished. (e) High power field in the basal zone of control. 
Arrows show mitosis. (f) High power field in the basal zone of GD11,12-treated 
group. Arrowheads show apoptotic cells, characterized by pyknosis or karyorrhexis. 
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Fig. 5. Histopathological findings of placentas on GD15. (L) Labyrinth zone, (B) 
Basal zone, (D) Decidua basalis, (S) Spinal artery, (Gly) Glycogen cell-islands, 
Glycogen cell- -treated group. 
(c) GD13,14-treated group. A marked decrease in glycogen cell-islands and an 
inhibition of the interstitial invasion of glycogen cell-like trophoblasts into metrial 
gland were detected in the GD11,12-treated group. 
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Fig. 6. Immunohistochemical expression of Phospho-Histone H3 (a and b) and 
TUNEL-positive cells (c and d) in basal zone on GD13. (L) Labyrinth zone, (B) Basal 
zone. Bar=30 -treated group. In the 
GD11,12-treated group, there were decreases in Phospho-Histone H3-positive cells 
and increases in TUNEL-positive cells on GD13. 
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Fig. 7. Number of Phospho-Histone H3-positive cells and TUNEL-positive cells in 
the labyrinth and basal zones. : Control. : GD11,12-treated group. : 
GD13,14-treated group. Values are expressed as means ± SE. *: P<0.05, compared 
with control (Student's t-test).
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CHAPTER 2 
Effect of Methotrexate on Neuroepithelium in the Rat Fetal Brain 
28 
2.1 Introduction 
A folate antagonist, methotrexate (MTX), inhibits dihydrofolate reductase that 
reduces dihydrofolate to tetrahydrofolate. MTX therefore limits the availability of 
one-carbon fragments necessary for the synthesis of purines and interferes with the 
conversion of deoxyuridylate to thymidylate in the synthesis of DNA and cell 
proliferation (Lloyd et al., 1999; Genestier et al., 2000; Hyoun et al., 2012). MTX is 
known to induce apoptosis, and the mechanism of MTX-induced apoptosis is 
considered to be associated with the up-regulation of p53 and p21 proteins 
(Kobayashi et al., 2002; Spurlock et al., 2012), repression of the induction of c-Jun 
N-terminal kinase (JNK) activity, expression of the CD95 receptor/ligand system 
(Müller et al., 1997) and reactive oxygen species (Herman et al., 2005; Spurlock et al., 
2012). 
MTX has been used in the treatment of malignancy, autoimmune and 
inflammatory diseases and gestational trophoblast disease (Cuellar and Espinoza, 
1997; DeLoia et al., 1998; Genestier et al., 2000). MTX is also used as an 
abortifacient, both for the voluntary termination of pregnancy and for the medical 
management of ectopic pregnancy (Kozma and Ramasethu, 2011). Medical treatment 
protocols for MTX were established in the 1980s and have become a widely accepted 
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primary treatment for unruptured ectopic pregnancy (Pisarska et al., 1998; Lipscomb, 
2007; Practice Committee of American Society for Reproductive Medicine, 2008). In 
humans, MTX embryopathy results from failed pregnancy termination with MTX or 
when mothers who are taking MTX for medical reasons become pregnant 
inadvertently (Bawle et al., 1998; Seidahmed et al., 2006; Corona-Rivera et al., 2010; 
Hyoun et al., 2012). The anomalies of MTX embryopathy include nervous system 
anomalies, growth deficiency, craniofacial deformities and skeletal defects (Lloyd et 
al., 1999; Hyoun et al., 2012). As the central nervous system anomalies in MTX 
embryopathy, alobar/semilobar holoprosencephaly (Seidahmed et al., 2006; 
Corona-Rivera et al., 2010), cerebellar hypoplasia (Seidahmed et al., 2006), agenesis 
of the corpus callosum (Seidahmed et al., 2006) and microcephaly (Bawle et al., 1998; 
Garcia-Minaur and Botella, 2000) have been reported. However, there are few reports 
to examine the brain anomalies in MTX embryopathy histopathologically, and their 
detailed histopathogical findings or their detailed pathogenesis remain unclear. In 
experimental animals, prenatal MTX exposure reportedly induced anomalies of the 
brain in chicken (Zamenhof, 1985) and rabbits (Jordan et al., 1977). In rabbit, MTX 
administration on gestation days (GD) 10-12 or GD 12 caused hydrocephalus (Jordan 
et al., 1977; DeSesso and Goeringer, 1992). However, there are few reports to date 
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describing damage to the fetal brain following MTX administration to dams, and 
detailed effects of prenatal MTX treatment on fetal brain have been not completely 
elucidated even in experimental animals. Therefore, in the present study, we examined 
histopathologically the time-dependent changes of fetal brain following MTX 
administration to their dams on GD 13 to clarify pathogenesis of MTX-induced brain 
anomalies in fetuses.  
2.2 Materials and methods 
2.2.1 Animals  
All experiments were performed using female Wistar Imamichi rats, 9 - 10 
weeks of age, 218.45 ± 2.09 g (mean ± SE) in weight, and obtained from the Institute 
of Animal Reproduction (Kasumigaura, Japan). The animals were reared in a room 
with the temperature controlled at 22 ± 2oC, humidity at 50 ± 5%, with ventilation 11 
times per hr, lighting at 12:12-hr light/dark cycle (light cycle, 7:00 - 19:00) and given 
standard chow (CE-2; Nihon Clea, Tokyo, Japan). The present experiments were 
performed following the provisions approved by the Animal Research Committee of 
Tottori University. 
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2.2.2 Experimental design 
A total of 40 animals were divided into two groups as follows: (1) 
saline-treated control rats (n=20), (2) MTX-treated rats (n=20). MTX (Pfizer Japan 
Inc., Tokyo, Japan) was dissolved in saline. Day 0 of gestation (GD 0) was designated 
as the day when the presence of a vaginal plug was identified. The rats received 
intraperitoneal injections (i.p.) with MTX (30 mg/kg body weight) or saline (the 
control) on GD 13. The specific timing of MTX administration was selected, because 
the injection of DNA damaging chemicals, such as ethylnitrosourea (ENU) 
(Katayama et al., 2000; 2001; 2005), 6-mercaptopurine (6-MP) (Kanemitsu et al., 
2009a), busulfan (Ohira et al., 2013), T-2 toxin (Sehata et al., 2004), 
1- -D-arabinofuranosylcytosine (Ara-C) (Yamauchi et al., 2004), 5-azacytidine 
(5AzC) (Ueno et al., 2002a; 2002b) and 5-Fluorouracil (5-Fu) (Yamaguchi et al., 2009) 
on GD13 induced apoptosis in neuroepithelial cells of telencephalon in rat fetal brain. 
The dose level in the present study was decided, because this dose was equivalent to 
10% of the LD50 in intraperitoneal injection in rats (Johnson et al., 1994) or 15 % - 
30 % of dosage used in high-dose cancer therapy in human (Hiraga et al., 1999; 
Komatsu et al., 1990). Fetus samples were collected under pentobarbital anesthesia 
(100 mg/kg, i.p.) 6, 12, 24, 36 and 48 hr, respectively, after MTX administration. 
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They were removed from the uterus and weighed, and their body lengths were 
measured.  
2.2.3 Histopathological examination 
For histopathological examination, all fetuses were fixed in 10% neutral 
buffered formalin and then embedded in paraffin. The tissues of telencephalon, 
diencephalon, mesencephalon and metencephalon in 12 fetal brain samples per group 
consisted of 3 fetuses ramdomly selected per dam in each group were sectioned at 2 
ematoxylin and eosin and examined with light 
microscopy. The number of pyknotic cells or mitotic cells was counted from over 
1,000 neuroepithelial cells in the telencephalon, diencephalon, mesencephalon and 
metencephalon for each fetus by light microscopy, and the pyknotic index and mitotic 
index were calculated as the percentage of pyknotic cells or mitotic cells from out of 
the total number of neuroepithelial cells counted. 
2.2.4 TUNEL method 
DNA-fragmented neuroepithelial cells in telencephalon were detected by 
terminal deoxynucleotidyl-transferase (TdT)-mediated deoxyuridine 
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triphosphate-digoxigenin (dUTP) nick-end labeling (TUNEL), which was performed 
using an in situ apoptosis detection kit (Trevigen, Inc., Gaithersburg, MD, U.S.A.). 
The number of TUNEL-positive cells was obtained from over 1,000 neuroepithelial 
cells in the telencephalon for each fetus by light microscopy, and the TUNEL-index 
was calculated as the percentage of TUNEL-positive cells out of the total number of 
neuroepithelial cells counted. 
2.2.5 Immunohistochemical examinations of rat fetuses 
Immunohistochemical staining was performed by a labeled-polymer method 
using Histofine Simple Stain MAX-PO (R) (Nichirei, Tokyo, Japan). To retrieve the 
antigen, tissue sections for the detection of cleaved caspase-3 antigen were immersed 
in citrate buffer, pH 6.0 (Dako, Glostrup, Denmark) and autoclaved for 15 min at 
121oC; and tissue sections for the detection of phospho-histone H3 antigen were 
immersed in citrate buffer, pH 6.0 (Dako) and microwaved for 15 min. Endogenous 
peroxidase activity was quenched by immersing the sections in 3% hydrogen peroxide 
in methanol for 15 min. The sections were incubated with the cleaved caspase-3 rabbit 
polyclonal antibody (1:300 dilution; Cell Signaling Technology, Inc., Danvers, MA, 
U.S.A.) at 4oC overnight; and the sections were incubated with the phospho-histone 
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H3 rabbit monoclonal antibody (1:1,500 dilution; Abcam, Tokyo, Japan) for 30 min at 
room temperature. Then, these sections were treated with Histofine Simple Stain 
MAX-PO (R) (Nichirei) for 30 min at room temperature. They were exposed to a 
3,3´-diaminobenzidine solution containing hydrogen peroxide (Nichirei) to facilitate a 
 The 
number of cleaved caspase-3- or phospho-histone H3-positive cells was counted from 
over 1,000 neuroepithelial cells in the telencephalon for each fetus by light 
microscopy, and the cleaved caspase-3- or phospho-histone H3-index was calculated 
as the percentage of cleaved caspase-3- or phospho-histone H3-positive cells out of 
the total number of neuroepithelial cells counted. 
2.2.6 Statistical analysis
Means ± standard error (SE) of the individual litter value was calculated. The 
data were analyzed with an F-
t- t-test was employed when variances were not 




2.3.1 Effects of MTX on rat fetuses 
Six, 12 and 24 hr after MTX treatment, there were no significant differences in 
the number of living fetuses per litter and the fetal mortality rates between the control 
group and MTX-treated group (Table 1). The number of living fetuses significantly 
declined, and fetal mortality rates significantly increased at 36 hr in the MTX-treated 
group, compared to those of the control group (Table 1). Almost all fetuses died by 48 
hr after MTX treatment (Table 1). 
2.3.2 Histopathological findings of rat fetal brain 
In the control group, pyknotic changes in neuroepithelial cells were rarely 
observed in any layers of the telencephalic wall throughout the experimental period 
(Figs. 1 and 2).
Six hr after treatment in the MTX-treated group, pyknotic neuroepithelial cells 
appeared in the telencephalic wall and scattered throughout that wall (Fig. 1B). Then, 
12 - 36 hr after MTX treatment, pyknotic neuroepithelial cells drastically increased 
and were diffusely distributed throughout the telencephalic wall (Figs. 1C - E and 2). 
At 36 hr, neuroepithelial cells were eliminated and showed low cell density in the 
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telencephalon of MTX-treated group (Fig. 1E). Although mitotic neuroepithelial cells 
were located along the ventricular layer of the telencephalic wall in the control group, 
they were rarely observed in the same region at 6 - 36 hr in the MTX-treated group 
(Fig. 1B - E). 
In the telencephalon of the control group, TUNEL-positive neuroepithelial 
cells were rarely observed in any layers of the telencephalic wall throughout the 
experimental period (Figs. 3A and 4). Most of the pyknotic neuroepithelial cells were 
positively stained by the TUNEL method at 12, 24 and 36 hr in the MTX-treated 
group (Fig. 3C - E), while there were few pyknotic neuroepithelial cells positively 
stained by the TUNEL method at 6 hr (Fig. 3B). In the MTX-treated group, the index 
of TUNEL-positive neuroepithelial cells in the telencephalic wall significantly 
increased at 12 and 24 hr and peaked at 36 hr (Fig. 4). 
Cleaved caspase-3-positive neuroepithelial cells were rarely observed in the 
telencephalon of control group throughout the experimental period (Figs. 5A and 6), 
although in the MTX-treated group, almost all pyknotic neuroepithelial cells were 
immunohistochemically positive for cleaved caspase-3 throughout the experimental 
period (Fig. 5B - E). In the MTX-treated group, the index of cleaved 
caspase-3-positive neuroepithelial cells in the telencephalon significantly increased at 
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6, 12 and 24 hr and peaked at 36 hr (Fig. 6). 
Phospho-histone H3-positive neuroepithelial cells were located along the 
ventricular layer of the telencephalic wall in the control group, while there were fewer 
phospho-histone H3-positive cells at 6 - 36 hr in the same region of the MTX-treated 
group than in the control group (Fig. 7A - E). The index of phospho-histone 
H3-positive neuroepithelial cells in telencephalon decreased significantly at 6 hr 
compared with the control group and maintained that low level throughout the 
experimental period (Fig. 8).  
In the MTX-treated group, pyknotic indices of telencephalon and 
diencephalon significantly increased at 12 - 36 hr, and those of the mesencephalon 
significantly increased at 24 and 36 hr, compared to the control group (Table 2). The 
pyknotic index of metencephalon significantly increased at 36 hr compared to control 
group, and it showed a clearly lower value, compared to those of the telencephalon, 
diencephalon and mesencephalon (Table 2). In the MTX-treated group, there were
fewer pyknotic neuroepithelial cells in the metencephalon than in the telencephalon, 
diencephalon and mesencephalon. In the MTX-treated group, while mitotic indices of 
telencephalon, diencephalon and mesencephalon decreased significantly at 6 - 36 hr, 




It has been reported that microcephaly can occur as one of the central nervous 
system anomalies of MTX embryopathy in humans (Bawle et al., 1998; 
Garcia-Minaur and Botella, 2000). The pathogenesis of microcephaly was closely 
associated with excessive neuronal death (Furukawa et al., 2004; Takano et al., 2006; 
Passemard et al., 2013). The cause of MTX-induced microcephaly may be also 
associated with excessive neuronal death. In the present study, the majority of 
pyknotic neuroepithelial cells in the telencephalic wall were positive for TUNEL 
staining and cleaved caspase-3. Cleavage of caspase-3 is known to be involved in cell 
apoptosis, and is recognized as an apoptosis marker (Gown and Willingham, 2002). 
These results indicate that pyknotic changes induced by MTX in the present study are 
caused by apoptosis. In the present study, pyknotic neuroepithelial cells in the 
telencephalon at 6 hr were positive for cleaved caspase-3, but negative for TUNEL 
staining. This result may reflect that the cleavage of caspase-3 precedes DNA 
fragmentation in the process of the neuroepithelial cell apoptosis induced by MTX.  
The previous studies showed that DNA-damaging chemical administration at 
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GD 12 or 13 induces apoptosis in neuroepithelial cells of the telencephalic wall of 
fetal brain (Katayama et al., 2000; 2001; Ueno et al., 2002a; 2002b; Woo et al., 2003; 
Katayama et al., 2005; Nam et al., 2006; Yamaguchi et al., 2009; Ohira et al., 2013). 
These apoptotic neuroepithelial cells are mainly observed in the dorsal layer after 
treatment with ENU (Katayama et al., 2000; 2001; 2005; Doi, 2011) in the medial to 
dorsal layer after treatment with hydroxyurea (Woo et al., 2003), 5-Fu (Yamaguchi et 
al., 2009; Doi, 2011), busulfan (Ohira et al., 2013) and etoposide (Nam et al., 2006) 
and in the ventral to medial layers after treatment with 5AzC (Ueno et al., 2002a; 
2002b; Doi, 2011). In the present study, apoptotic neuroepithelial cells localized 
throughout all layers of the telencephalic wall, but their distribution was different 
from those of apoptotic neuroepithelial cells induced by the above-mentioned other 
DNA-damaging chemicals (Table 4). It is known that in the ventricular zone of fetal 
brain, the positions of the nuclei of neuroepithelial cells are correlated with their cell 
cycle phase (Doi, 2011). S-phase nuclei are located in the dorsal layer of the 
ventricular zone (Doi, 2011). They migrate inward during the G2 phase, and mitosis 
occurs at the ventricular surface (Doi, 2011). Then, they migrate outward during the 
G1 phase and enter the S phase again (Doi, 2011). In brief, the nuclei during the G1 or 
G2 phase are in the middle layer of the ventricular zone. The distribution of apoptotic 
40 
neuroepithelial cells throughout all layers of the telencephalic wall in the present 
study may reflect that MTX induces apoptosis of neuroepithelial cells in all phases of 
the cell cycle or that apoptosis occurs independently of cell cycle arrest. Whereas a 
previous study showed that apoptosis of the human hepatoma HepG2 cells induced by 
folate deficiency was specific for S- and/or G2-phase arrest (Huang et al., 1999), the 
present result suggests that MTX induces apoptosis of neuroepithelial cells through a 
mechanism other than S- and/or G2-phase arrest. 
In the present study, the pyknotic, TUNEL and cleaved caspase-3 indices of 
neuroepithelial cells in the telencephalon peaked 36 hr after treatment with MTX at 
GD 13 (Table 5). The index of pyknotic cells in the telencephalon peaked 9 - 12 hr 
after treatment with Ara-C (Yamauchi et al., 2004) and ENU (Katayama et al., 2001). 
The index of TUNEL-positive cells peaked 12 hr after treatment with T-2 toxin 
(Sehata et al., 2004) and 5AzC (Ueno et al., 2002a), and the index of cleaved 
caspse-3-positive cells peaked 48 hr after treatment with busulfan (Ohira et al., 2013). 
On the other hand, in the present study, mitotic and phospho-histone H3 indices in 
telencephalon treated with MTX decreased significantly at 6 hr and maintained that 
low level throughout the experimental period (Table 5). The mitotic cell index in the 
telencephalon significantly decreased at 30 hr and reached its lowest level 36 hr after 
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treatment with 6-MP (Kanemitsu et al., 2009a), while the mitotic cell index peaked 6 
hr, decreased thereafter and reached the minimal level 24 hr after treatment with 
5AzC (Ueno et al., 2002b). The index of phospho-histone H3-positive cells 
significantly decreased at 24 hr and reached its minimal level 48 hr after treatment 
with busulfan (Ohira et al., 2013), while it reached the lowest level 36 hr after 
treatment with 6-MP (Kanemitsu et al., 2009b). The distribution of pyknotic 
neuroepithelial cells and the time-course changes of the indices of pyknotic and 
mitotic neuroepithelial cells in the telencephalic wall were different from those of the 
previously-mentioned other DNA-damaging chemicals. These differences may reflect 
the disparity in mechanisms of apoptosis and the inhibition of cell proliferation in 
neuroepithelial cells among DNA-damaging chemicals. Further investigations should 
be conducted to clarify the true cause of these differences. 
In the present study, MTX induced fewer pyknotic changes of neuroepithelial 
cells in the metencephalon than in other brain regions. The result of a previous study 
suggested that cell-proliferative activity was associated with the sensitivity to MTX 
(Sun et al., 2013). The different pyknotic indices of the MTX-treated group among the 
brain regions in the present study may reflect the disparity of cell-proliferative activity. 
In a previous study (Zamenhof, 1985), MTX inhibited the development of individual 
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brain parts to varying degrees in chick embryos. The same study suggested that the 
different effects of MTX on various brain parts may be due to different schedules of 
cell proliferation among individual brain parts. Other previous studies demonstrated 
that busulfan or 5-Fu treatment at GD13 in rat fetus induced pyknotic changes of 
neuroepithelial cells in metencephalon to the same degree as those in diencephalon 
and mesencephalon (Ohira et al., 2009; Yamaguchi et al., 2009). These results suggest 
that there are differences in sensitivities to MTX, busulfan and 5-Fu of neuroepithelial 
cells in the metencephalon. 
There are several studies describing brain malformation induced by MTX in 
human and rabbits (Jordan et al., 1977; Seidahmed et al., 2006; Corona-Rivera et al., 
2010). A report of Seidahmed et al. (2006) described that 2.5 mg of MTX 3 times a 
day for 7 days, for a total of 52.5 mg at 6 weeks of gestation, induced alobar 
holoprosencephaly, cerebellar hypoplasia and agenesis of the corpus callosum in 
human. Corona-Rivera et al. (2010) reported that MTX 5mg/day treatment for 14 
days at the 5th week post-conception induced brain anomalies including semilobar 
holoprosencephaly and hydrocephalus in human. In rabbits, MTX 19.2 mg/kg 
administration during GD 10-15 induced various anomalies including hydrocephalus 
(Jordan et al., 1977). In the present study, single dose-administration of MTX 30 
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mg/kg on GD 13 induced fetal death 48 hr after treatment, and the cause of fetal death 
in the present study may be relevant to dose, number and timing of MTX 
administration. 
In conclusion, MTX administration of 30 mg/kg on GD 13 induced apoptosis 
of neuroepithial cells and inhibited mitosis of these cells in telencephalon 6 - 36 hr 
after treatment. The distribution of apoptotic neuroepithelial cells in the telencephalic 
wall and the whole brain and the time-course changes of the indices of apoptotic and 
mitotic neuroepithelial cells were different from other DNA-damaging chemicals 
reported previously. While the detailed mechanisms of MTX-induced neuroepithelial 
cell damage in fetal brain remain unclear, the present results provide fundamental 
information about the fetal brain damage induced by MTX. The present results serve 
to elucidate the pathogenesis of nervous system anomalies resulting from failed 
pregnancy termination with MTX or when mothers who are taking MTX for medical 
reasons become pregnant inadvertently. To our knowledge, this is the first report 
demonstrating histopathological findings of fetal brain damage induced by MTX. 
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Dead fetus ratio (%) 
6 hr Control 4 58 14.59 ± 0.50 9.03 ± 3.03
 MTX 4 57 14.25 ± 0.63 3.14 ± 1.82 
12 hr Control 4 56 14.00 ± 0.41 7.93 ± 3.00
 MTX 4 63 15.75 ± 2.50 15.92 ± 10.67
24 hr Control 4 58 14.50 ± 1.44 7.63 ± 4.81
 MTX 4 57 14.25 ± 0.95 6.48 ± 4.44
36 hr Control 4 62 15.50 ± 1.19 3.58 ± 3.58
 MTX 4 44  11.00 ± 0.41* 30.30 ± 5.41**
48 hr Control 4 56 14.00 ± 1.00 4.73 ± 3.15
 MTX 4 1    0.25 ± 0.25 98.53 ± 1.48***
Values are expressed as means ± SE. 
*, **, ***: Significantly different from control at P<0.05, P<0.01, P<0.001, 
respectively (Student's t-test). 
t-test). 
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Table 2. Pyknotic index (%) in rat fetal brain treated by MTX 
  6 hr 12 hr 24 hr 36 hr 
Telencephalon Control 0.03 ± 0.03 0.05 ± 0.05 0.10 ± 0.07 0.28 ± 0.14
 MTX 2.68 ± 0.85 19.98 ± 2.45 34.82 ± 2.17 43.33 ± 3.07
Diencephalon Control 0.61 ± 0.28 0.79 ± 0.30 0.66 ± 0.36 0.81 ± 0.30
 MTX 1.61 ± 0.38 14.31 ± 1.53 20.88 ± 2.44   20.65 ± 1.67
Mesencephalon Control 0.39 ± 0.04 0.41 ± 0.11 0.29 ± 0.11 0.47 ± 0.12
 MTX 0.37 ± 0.18 7.78 ± 2.88 26.90 ± 5.45   36.56 ± 3.99
Metencephalon Control 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.07 ± 0.05
 MTX 0.04 ± 0.02 0.00 ± 0.00 2.34 ± 1.52 3.88 ± 0.72
Values are expressed as means ± SE (%).
respectively (Welch's t-test). 
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Table 3. Mitotic index (%) in rat fetal brain treated by MTX 
  6 hr 12 hr 24 hr 36 hr 
Telencephalon Control 4.56 ± 0.20 4.48 ± 0.25 4.82 ± 0.24 4.50 ± 0.09
 MTX 0.53 ± 0.05  0.24 ± 0.03 0.16 ± 0.08*** 0.22 ± 0.13***
Diencephalon Control 3.01 ± 0.28 3.30 ± 0.33 2.56 ± 0.36 3.66 ± 0.28
 MTX 0.37 ± 0.08*** 0.57 ± 0.09*** 0.37 ± 0.09 0.40 ± 0.20***
Mesencephalon Control 3.64 ± 0.43 3.76 ± 0.35 3.51 ± 0.44 4.53 ± 0.34
 MTX  0.64 ± 0.17*** 0.96 ± 0.10*** 0.22 ± 0.07 1.13 ± 0.27***
Metencephalon Control 3.12 ± 0.64 3.25 ± 0.25 1.37 ± 0.25 1.25 ± 0.10
 MTX 0.67 ± 0.08 1.40 ± 0.35** 1.53 ± 0.47 1.60 ± 0.26
Values are expressed as means ± SE (%).
**, ***: Significantly different from control at P<0.01, P<0.001 respectively 
(Student's t-test). 
Significantly different from control at P<0.05, P<0.01, P<0.001 
respectively (Welch's t-test). 
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Table 4. Location of apoptotic cells in the ventricular zone of telencephalon after 
treatment with DNA-damaging chemicals 
Location of apoptotic cells  
in the ventricular zone of telencephalon 
Ethylnitrosourea Dorsal layer 
Hydroxyurea, Busulfan, 
Etoposide, 5-Fluorouracil 
Medial to dorsal layers 
5-Azacytidine Ventral to medial layers 
Methotrexate All layers 
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Table 5. Timing of the maximal level of cell death indices and minimal level of cell 
proliferation indices in the telencephalon after DNA-damaging chemicals treatment 
 Maximal level of cell death indices Minimal level of cell proliferation indices
 Pyknosis TUNEL Cleaved caspase-3  Mitosis Phospho-histone H3 
1- -D-arabinofuranosylcytosine  9 hr 
Ethylnitrosourea 12 hr 
T-2 toxin  12 hr 
5-azacytide  12 hr   24 hr 
Busulfan  48 hr   48 hr 
6-Mercaptopurine   36 hr 36 hr 
Methotrexate 36 hr 36 hr 36 hr 6 - 36 hr 6 - 36 hr 
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Fig. 1. Histopathological findings of telencephalic wall of rat fetal brain in the control 
group 6 hr after treatment (A) and the MTX-treated group at 6 (B), 12 (C), 24 (D) and 
36 hr (E), respectively. (A) Arrowheads indicate mitotic cells. (B) Arrows indicate 
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Fig. 2. Changes in the pyknotic index (%) in telencephalic wall of rat fetal brain. 
P<0.05, P<0.001, respectively (Welch's t-test). 
51 
Fig. 3. TUNEL-positive cells in telencephalic wall of rat fetal brain in the control 
group 6 hr after treatment (A) and the MTX-treated group at 6 (B), 12 (C), 24 (D) and 
36 hr (E
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Fig. 4. Changes in the TUNEL index (%) in telencephalic wall of rat fetal brain. 
P<0.01, P<0.001, respectively (Welch's t-test). 
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Fig. 5. Immunohistochemical expression of cleaved caspase-3 in telencephalic wall of 
rat fetal brain in the control group 6 hr after treatment (A) and the MTX-treated group 
at 6 (B), 12 (C), 24 (D) and 36 hr (E
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Fig. 6. Cleaved caspase-3 index. V
Significantly different from control at P<0.05, P<0.001, respectively (Welch's t-test). 
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Fig. 7. Immunohistochemical expression of phospho-histone H3 in telencephalic wall 
of in rat fetal brain in the control group 6 hr after treatment (A) and the MTX-treated 
group at 6 (B), 12 (C), 24 (D) and 36 hr (E), respectively . 
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Fig. 8. Phospho-histone H3 index. Values are expressed as means ± SE. ***: 
Significantly different from control at P<0.001 (Student's t-
different from control at P<0.01 (Welch's t-test). 
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GENERAL CONCLUSION 
In the first chapter, we aimed to obtain clues to clarify the role of the placenta 
in the induction of MTX-induced fetal developmental disability. MTX treatment at 0.2 
mg/kg/day during GDs 13-14 induced few pathological changes in the placenta, 
whereas MTX administration during GDs 11-12 induced growth arrest of basal and 
labyrinth zones, leading to small placentas, in addition to the increase of fetal 
mortality rates and the decrease of fetal weights. Particularly, the hypoplasia of the 
basal zone induced by MTX exposure during GDs 11-12 was more severe than that of 
the labyrinth zone. Moreover, a significant increase in apoptotic cells and a significant 
decrease in mitotic cells were detected in the basal zone of GD11- and 12-treated 
group. These results suggested that the component cells of the basal and labyrinth 
zones on GDs 11-12 are more highly sensitive to MTX than those during GDs 13-14 
and that MTX affects the component cells of the basal zone more strongly than those 
of the labyrinth zone. While it is speculated that basal zone hypoplasia correlates with 
the fetal mortality rate and decrease of fetal weights, the fact remains unclear. To our 
knowledge, this is the first published report demonstrating the sequential 
histopathological findings of placental growth retardation induced by MTX. 
In the second chapter, the study aimed to clarify the pathogenesis of 
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MTX-induced brain anomalies in fetuses. MTX administration of 30 mg/kg on GD 13 
induced apoptosis of neuroepithial cells and inhibited proliferative activity of these 
cells in the ventricular zone of telencephalon. The time-course changes of the indices 
of apoptosis and cell proliferation were different from other DNA-damaging 
chemicals reported previously. These differences may reflect the disparity in 
pharmacokinetics and mechanisms of DNA damage, apoptosis and the inhibition of 
cell proliferation in neuroepithelial cells among DNA-damaging chemicals. In 
addition, the distribution of apoptotic neuroepithelial cells throughout all layers of the 
telencephalon in the present study, and it is different from other DNA-damaging 
chemicals. It is speculated that MTX induces apoptosis of neuroepithelial cells in all 
phases of the cell cycle or that apoptosis occurs independently of cell cycle arrest. The 
present results provide fundamental information about the MTX-induced fetal brain 
damage and contribute to elucidate the pathogenesis of brain anomalies in MTX 
embryopathy. To our knowledge, this is the first study demonstrating the 
time-dependent histopathological findings of fetal brain damage induced by MTX, 
although the exact mechanisms of MTX-induced neuroepithelial cell damage in fetal 
brain need to be clarified by further study. 
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ABSTRACT 
In chapter 1, the sequential changes in the placenta from rats exposed to MTX 
were examined histopathologically. MTX was intraperitoneally administered at 0.2 
mg/kg/day during gestation days (GDs) 11-12 or GDs 13-14, and the placentas were 
sampled on GDs 13, 15, 17 and 21. The fetal mortality rates tended to increase 
throughout the experimental period, and fetal weights were significantly decreased on 
GD13 in the GD11,12-treated group. A significant reduction in placental weights was 
detected on GDs 13 and 15 in the GD11,12-treated group. Histopathologically, in the 
GD11,12-treated group, a significant thinning of the basal zone was detected 
throughout the experimental period, whereas the thickness of the labyrinth zone 
decreased significantly during GDs 13-17. The severity of thinning of the basal zone 
was higher than that of the labyrinth zone. In addition, a marked decrease in glycogen 
cell-islands in the basal zone was detected on GD 15. A significant decrease in 
Phospho-Histone H3-positive cells and a significant increase in TUNEL-positive cells 
were detected on GD 13 in the basal zone of the GD11,12-treated group. In the 
GD13,14-treated group, there were no other significant changes in placentas and 
fetuses throughout the experimental period other than thinning of the labyrinth zone 
on GD 17. These results suggest that component cells of the basal and labyrinth zones 
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during GDs 11-12 are more highly sensitive for MTX than those during GDs 13-14 
and MTX affects the component cells of basal zone more strongly than those of the 
labyrinth zone. 
In chapter 2, the study was aimed to elucidate the pathogenesis of the damage 
of fetal brain induced by MTX. Pregnant rats were treated with 30 mg/kg of MTX on 
gestation day 13, and fetal brains were examined histopathologically from 6 to 48 hr 
after the treatment. In the telencephalon of the control group, there were few pyknotic 
neuroepithelial cells throughout the experimental period. Six hr after MTX treatment, 
several pyknotic neuroepithelial cells scattered throughout the telencephalic wall. At 
12 - 36 hr, pyknotic neuroepithelial cells increased significantly and were diffusely 
distributed throughout the telencephalic wall. Neuroepithelial cells were eliminated 
and showed sparse cell density at 36 hr in the telencephalon. Almost all fetuses died at 
48 hr. Most of the pyknotic neuroepithelial cells were positively stained by the 
TUNEL method and positive for cleaved caspase-3. While mitotic and 
phospho-histone H3-positive neuroepithelial cells were located along the ventricular 
layer of telencephalon in the control group, they were rarely observed in the same 
region at 6 - 36 hr in the MTX-treated group. MTX induced few pyknotic changes to 
neuroepithelial cells in the metencephalon, compared to other parts of brain. The 
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distribution of apoptotic neuroepithelial cells and the time-course changes of the 
indices of apoptotic and mitotic neuroepithelial cells were different from those of 
other DNA-damaging chemicals reported previously. The difference may reflect the 
disparity in mechanisms of apoptosis and the inhibition of cell proliferation in 
neuroepithelial cells induced by MTX. 
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